MSB 3.21% $1.13 mesoblast limited

Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-809

  1. 3,952 Posts.
    lightbulb Created with Sketch. 1352
    Considering some fake news that has been published in regards to the comparison study I thought it a good idea to look into it a bit more. The study that I am looking at has a link attached to the announcement (1)
    Some really tragic data hear
    Out of 455 ventilated critical ill just 16 discharged, MSBs 12 patients could be in this group leaving just 9
    245 were still on ventilation unfortunately 162 go to the hospice or died group ...36% Now I know this is not 88% how ever as time goes on this % will unfortunately grow.
    This study has been reported in the media with Various head line results. We will be hearing a lot more about this in the near future.
    The outcomes of the 12 patients are outstanding. Make no mistake. Good luck all.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.